Benefits
Traditional short-term use for mild urinary discomfort
Long-standing traditional use (centuries in European and Native American medicine) for cystitis and urinary discomfort. The European Medicines Agency lists bearberry leaf under a traditional-use herbal monograph, which is a registration based on long-standing use rather than on proof that it works. Its wording covers relief of symptoms of mild recurrent lower urinary tract infection in adult women, once a doctor has ruled out anything serious, and it says not to use it for more than one week. Germany's Commission E, the herbal expert panel advising the BfArM, published a positive monograph in 1994, at a time when no controlled trial of bearberry leaf on its own existed. Neither is an efficacy approval. Two modern randomized trials have since tested it in women, and neither showed better symptom relief than its comparator; see the trial summaries below.
REGATTA trial: fewer antibiotic courses, but worse symptoms and more kidney infections
In the REGATTA trial, 398 women with suspected uncomplicated urinary tract infection at 42 German family practices were randomly assigned, double-blind, to uva ursi (207) or a single 3 g dose of fosfomycin (191). Antibiotic courses over 28 days were 63.6% lower in the uva ursi group (95% CI 53.6 to 71.4; p < 0.0001). That came at a price. Total symptom burden was 136.5% of the fosfomycin group (95% CI 122.7 to 151.9), which failed the trial's prespecified non-inferiority margin of 125%, and 8 women taking uva ursi developed pyelonephritis, a kidney infection, versus 2 on fosfomycin (mean difference 2.8; 95% CI 0.2 to 5.9; p 0.067). The authors concluded that uva ursi reduced antibiotic use but led to a higher symptom burden and more safety concerns than fosfomycin. That is a trade-off with a real downside, and it is a decision for a doctor, not a reason to self-treat.
In vitro antimicrobial activity (mechanism-based)
Arctostaphylos uva-ursi extracts inhibit growth of uropathogenic Gram-negative bacteria (E. coli, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae), Gram-positive (Staphylococcus aureus, S. saprophyticus), and Candida albicans in vitro. Activity attributed to hydroquinone metabolites. Crude extract is reported to be more potent than purified arbutin alone, which suggests other constituents such as tannins and flavonoids contribute. These are laboratory dish results; no study cited on this page has shown uva ursi killing bacteria in a person, and the two human trials that tested it found no symptom benefit over placebo or fosfomycin.
An old prevention report that has not been repeated
A small 1993 report (Larsson, Jonasson and Fianu, Current Therapeutic Research, 57 women) described fewer cystitis recurrences over a year. It tested UVA-E, a combination of uva ursi and dandelion, not uva ursi on its own, it was called preliminary by its own authors, and it is not indexed in PubMed, so it cannot be checked the way the modern trials can. However, this finding has not been replicated in modern rigorous trials, and the EMA limits chronic use due to hydroquinone toxicity concerns. Should not be used long-term.
Mechanism of action
Arbutin → hydroquinone metabolic activation in urine
Oral arbutin is hydrolyzed by intestinal flora and absorbed; conjugated to glucuronide/sulfate in liver; excreted in urine. In alkaline urine (pH >8), the conjugates dissociate to free hydroquinone, which has antibacterial activity. This is why traditional dosing emphasizes alkaline diet (vegetables, baking soda) — though clinical relevance of urinary alkalinization is debated. Acidic urine reduces antimicrobial efficacy.
Urease inhibition (limited)
Some uva ursi components partially inhibit bacterial urease, theoretically interfering with struvite stone formation and Proteus pathogenesis. However, OTC plant preparations had limited effectiveness as inhibitors of urease activity from S. saprophyticus — questioning practical clinical relevance.
Anti-adherence and biofilm inhibition
Uva ursi extracts inhibit bacterial adherence to bladder epithelium and biofilm formation in vitro. Tannins and flavonoids likely contribute to this effect beyond the arbutin/hydroquinone axis. May explain part of the symptomatic benefit observed historically — preventing colonization rather than killing established infection.
Mild astringent and anti-inflammatory effects
High tannin content (10-20% of dry leaf) produces astringent effect on urothelial mucosa. Plus mild anti-inflammatory activity on bladder inflammation. This is a proposed route to symptom relief that is independent of any antimicrobial action, but it remains theory: the largest placebo-controlled trial found no symptom difference from placebo.
Clinical trials
2x2 factorial placebo-controlled randomized trial (Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, Maishman T, Galanopoulou A, Flower A, Eyles C, Willcox M, Hay AD, van der Werf E, Gibbons S, Lewith G, Little P, Clin Microbiol Infect 25(8):973-980, doi:10.1016/j.cmi.2019.01.011).
382 women aged 18-70 with UTI symptoms (dysuria, urgency, frequency) in UK primary care. Randomized to uva-ursi extract (20% arbutin, 3,600 mg/day = 720 mg arbutin) ± ibuprofen advice (1,200 mg/day) ± placebo. All received delayed antibiotic prescription.
Negative trial for uva ursi. ITT analysis of mean frequency symptom score: no evidence of a difference between uva ursi and placebo (-0.06, 95% CI -0.33 to 0.21, p=0.661). No significant reduction in antibiotic consumption with uva ursi (39.9% vs 47.4%, OR 0.59, 95% CI 0.22-1.58, p=0.293). Ibuprofen advice produced significant antibiotic reduction (34.9% vs 51.0%) — but uva-ursi did not. Editorial commentary concluded 'uva-ursi and ibuprofen not ready for primetime' for UTI antibiotic-sparing.
Double-blind, randomized, controlled comparative effectiveness trial (Gágyor I, Hummers E, Schmiemann G, Friede T, Pfeiffer S, Afshar K, Bleidorn J. Clin Microbiol Infect 2021;27(10):1441-1447, doi:10.1016/j.cmi.2021.05.032, PMID 34111592).
398 adult women with suspected uncomplicated urinary tract infection at 42 family practices in Germany, randomly assigned to uva ursi extract 105 mg, 3 x 2 tablets daily for 5 days (n=207), or a single 3 g dose of fosfomycin (n=191). Both groups also took the matching placebo of the other treatment, so the trial was fully blinded. Antibiotic therapy provided in UU group only on persistent/worsening symptoms.
The trial had two primary outcomes and split them. Antibiotic courses on days 0 to 28 were 63.6% lower with uva ursi (95% CI 53.6 to 71.4; p < 0.0001), a clear win. The co-primary non-inferiority outcome failed: total symptom burden on days 0 to 7 was 136.5% of the fosfomycin group (95% CI 122.7 to 151.9), well past the prespecified 125% margin. Eight women in the uva ursi group developed pyelonephritis, an ascending kidney infection, versus two on fosfomycin (mean difference 2.8; 95% CI 0.2 to 5.9; p 0.067). Other adverse events were similar between groups. The authors' own conclusion was that initial treatment with uva ursi reduced antibiotic use but led to a higher symptom burden and more safety concerns than fosfomycin.
Larsson B, Jonasson A, Fianu S. Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Current Therapeutic Research 1993;53:441-443. This 1993 report is not indexed in PubMed, so it cannot be checked against a public abstract, and its own authors labelled it preliminary. The product tested, UVA-E, was a combination of uva ursi and dandelion, not uva ursi on its own.
57 women who had had at least three episodes of cystitis in the preceding year: 30 took UVA-E and 27 took placebo for one month, then were followed for a year.
No recurrence was reported in the 30 women on UVA-E versus 5 of 27 on placebo over the following year. This is the historical result behind uva ursi's European reputation, but it rests on one month of a two-herb combination in 57 women, reported once in 1993 and never repeated. However, modern view: long-term prophylactic use is now discouraged due to hydroquinone toxicity concerns and lack of replication in newer trials. EMA limits use to ≤7 days at a time, ≤5 episodes per year.